At Revitalize Peptide Lab: All peptide materials undergo third-party HPLC testing Each batch meets our 99% purity standard prior to release Products are handled under strict quality control procedures A mild, localized welt is often a biological response rather than a quality failure
FDA-Approved vs Research Compounds Understanding the distinction between FDA-approved peptides and research-only compounds is essential for evaluating safety: Category Examples Evidence Base Regulation FDA-Approved Semaglutide (Ozempic), Teriparatide (Forteo), Tesamorelin (Egrifta) Phase I-III clinical trials, post-market surveillance Prescription required, manufactured under cGMP Previously Approved Sermorelin (Geref withdrawn 2008) Clinical trial data exists, but product no longer marketed Research use only (currently) Research Only BPC-157, TB-500, Ipamorelin, KPV Preclinical data (varying depth), no completed human trials Sold for laboratory research, not human consumption For the complete list of FDA-approved peptides and their indications, see our FDA Approved Peptides List 2026 guide
5-amino-1MQ Appearance: Lyophilized powder in a sealed research vial Investigation of NNMT inhibition and its downstream metabolic effects Studies on NAD+ metabolism and energy homeostasis in preclinical models Development of analytical methods (HPLC/LC-MS) for small-molecule quantitation Stability and solubility assessment of 5-amino-1MQ under laboratory storage conditions For qualified research professionals and institutional laboratories
Most common side effects were gastrointestinal, with 24.5% of participants in the phase 2 obesity trial discontinuing efinopegdutide 10 mg due to AE however when the same dose was used with gradual escalation at the MASLD trial (starting dose 2.4 mg for 4 weeks, then 5 mg for 4 weeks and then 10 mg), only 5.6% of participants discontinued the medication due to AE
The goal is to maximize its regenerative and reparative benefits while minimizing any temporary adverse observations
